Results 111 to 120 of about 62,498 (301)

The case for increasing buprenorphine use as OST during Covid-19.

, 2021
[Please note, the Irish Pharmacist website (and the full text of this article) is for health professionals only.] Consultant in Addiction Psychiatry Dr Ciaran Somers analyses the potential advantages of an accelerated move to buprenorphine from ...
Somers, Ciaran
core  

Comparison of Buprenorphine-Naloxone and Buprenorphine Monotherapy in Opioid Dependent Pregnant Women [PDF]

, 2020
•The purpose of this literature review is to compare the use of buprenorphine-naloxone combination therapy to buprenorphine monotherapy as medication assisted therapy (MAT) for opioid dependent pregnant women.
Gillund, Ellie
core  

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings

BMC Primary Care
Background Medications for opioid use disorder (MOUD), including buprenorphine, are effective treatments for opioid use disorder (OUD) and reduce risk for overdose and death.
Stephanie A. Hooker, Colleen Starkey, Gavin Bart, Rebecca C. Rossom, Sheryl Kane, Anthony W. Olson   +5 more
doaj   +1 more source

Pharmacokinetics and pharmacodynamics of buprenorphine and sustained-release buprenorphine after administration to adult alpacas

, 2017
OBJECTIVE To determine pharmacokinetics and pharmacodynamics of buprenorphine after IV and SC administration and of sustained-release (SR) buprenorphine after SC administration to adult alpacas. ANIMALS 6 alpacas. PROCEDURES Buprenorphine (0.02 mg/kg, IV
Phillip Lerche, Richard M. Bednarski, John A. E. Hubbell, S. Bryce Dooley, Turi K. Aarnes, Jeffrey Lakritz   +5 more
core   +1 more source

Unlocking ‘stuckness’ and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic‐assisted therapy for substance use and mental health problems

Addiction, EarlyView.
Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove, Katrin Oliver, Michael Savic, Shalini Arunogiri   +3 more
wiley   +1 more source

The impact of harm reduction interventions on injection‐related bacterial infections among people who inject drugs: A systematic review

Addiction, EarlyView.
Abstract Background and aims Injection‐related bacterial infections represent a major but under‐recognised health issue among people who inject drugs (PWID). Harm reduction interventions (HRIs) like needle and syringe programmes (NSP) and opioid agonist treatment (OAT) could mitigate their burden.
Anthony Cousien, Lobna Tijani, Nadia Hachicha, Manon Godart, Mathieu Castry, Karen Champenois, Perrine Roux, Sylvie Deuffic‐Burban   +7 more
wiley   +1 more source

Prescribed pharmaceutical alternatives initiative coinciding with reductions in unregulated street opioid use among young people who use drugs: An interrupted time series analysis

Addiction, EarlyView.
Abstract Background and aims In British Columbia, Canada, an initiative was implemented in 2020 to reduce overdose mortality by prescribing pharmaceutical opioids (primarily hydromorphone) as a substitute for the toxic unregulated drug supply. This study estimated changes in the level and trend of unregulated opioid use and non‐prescribed hydromorphone
Erica McAdam, Mohammad Karamouzian, Michael John Milloy, Carmen Verdicchio, Eric C. Sayre, Kanna Hayashi, Thomas Kerr, Kora DeBeck   +7 more
wiley   +1 more source

Joint associations of recovery capital and polygenic risk with electronic health record observed remission and relapse in substance use disorder: Longitudinal evidence from the All of Us research program

Addiction, EarlyView.
Abstract Background and aims Recovery capital and genetic liability may be related to substance use disorder (SUD) remission through psychosocial and biologic pathways, but their joint association with remission course remains poorly understood. This question is clinically important because people entering remission differ in recovery resources and ...
Janaka V. Kosgolla, Douglas C. Smith
wiley   +1 more source

Methylenedioxymethamphetamine (MDMA)‐related fatal poisoning in Australia, 2016 to 2025: Trends, characteristics and toxicology

Addiction, EarlyView.
Abstract Aims To determine: (1) Population rates of fatal methylenedioxymethamphetamine (MDMA)‐related poisoning over the period 2016–2023, years with high closure rates in the National Coronial Information System (NDIS); (2) the case characteristics of known cases of fatal MDMA‐related poisoning, 2016–2025; and (3) whether there have been changes in ...
Shane Darke, Johan Duflou, Agata Chrzanowska, Michael Farrell, Julia Lappin, Amy Peacock   +5 more
wiley   +1 more source